This webinar takes place on Thursday November 21st between 15.00 and 15.30 CET / 14.00-14.30 GMT / 9.00-9.30 AM EST.

Follow the link to register for the webinar. Please note that the presentation will be given during the live event only and on demand viewing at a later date will not be possible. Contact us for any questions.

 

REGISTER FOR LIVE WEBINAR

 

THIS WEBINAR IS ARRANGED BY CELLECTRICON AB. FOR MORE INFORMATION ON THE HANDLING OF YOUR PERSONAL INFORMATION, SEE OUR PRIVACY POLICY.

 

Abstract:

Insoluble aggregates (Lewy bodies) consisting of misfolded alpha-synuclein accumulate in the nervous system of most Parkinson’s disease patients. This process can affect multiple cellular functions, eventually leading to neuronal death. From a drug discovery perspective, preventing protein aggregation or promoting protein clearance provide interesting opportunities as pharmacological intervention points.

In this webinar, we will present a high-capacity in vitro model of alpha-synuclein aggregation and how it was used to identify targets involved in the modulation of alpha-synuclein aggregation. Using lentiviral knock-down combined with high content imaging and analysis as well as gene expression analysis, targets were identified and validated. In addition to RNA knock-down approaches, the presented in vitro model could be used to evaluate how different modalities modulate alpha-synuclein aggregation and cell health and, together with orthogonal assays, be a useful tool in lead identification and lead optimization activities.

Presented by:

Linnea Strid Orrhult

Linnea joined the company in 2019 as an External Collaborations Manager. In her role, she designs and drives drug discovery projects for clients, mainly in the areas of neurodegeneration and neuroinflammation. Before joining Cellectricon, Linnea was a postdoctoral researcher at the University of Gothenburg studying the role of innate immunity after infection and hypoxia-ischemia in the neonatal brain and its barriers. She also worked as lab manager and research scientist leading projects focused on 3D printing of primary cells. Linnea received a PhD in Medicine from the University of Gothenburg in 2011, where she investigated the role of Toll like receptors for inflammation in the immature brain.